IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10906942 B1

PDFFull Text
Date of Patent:
Feb. 02, 2021

Filed:

May. 18, 2017

Vsv/ndv hybrid viruses for oncolytic therapy of cancer

Applicant:

Klinikum Rechts Der Isar Der Technischen Universität München, Munich, DE;

Inventors:

Oliver Ebert, Munich, DE;

Jennifer Altomonte, Munich, DE;

Assignee:

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN, Munich, DE;

Attorney:

Saliwanchik, Lloyd & Eisenschenk

Primary Examiner:

Nicole Kinsey White

Int. Cl.
CPC ...
C07K 14/005 (2006.01); A61K 9/00 (2006.01); A61K 35/766 (2015.01); A61K 38/16 (2006.01); A61K 38/47 (2006.01); A61K 45/06 (2006.01); C12N 9/24 (2006.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01); A61K 49/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 9/0019 (2013.01); A61K 9/0021 (2013.01); A61K 9/0085 (2013.01); A61K 35/766 (2013.01); A61K 38/162 (2013.01); A61K 38/47 (2013.01); A61K 45/06 (2013.01); A61K 49/00 (2013.01); C12N 9/2402 (2013.01); C12N 15/86 (2013.01); C12Y 302/01018 (2013.01); A61K 38/00 (2013.01); C07K 2319/50 (2013.01); C07K 2319/60 (2013.01); C12N 2760/18122 (2013.01); C12N 2760/20232 (2013.01); C12N 2760/20243 (2013.01); C12N 2810/6072 (2013.01);
Abstract

The present invention relates to recombinant oncolytic viruses comprising a vesicular stomatitis virus (VSV), wherein the glycoprotein (G protein) of VSV is deleted; and which comprises a modified fusion protein (F protein) of Newcastle disease virus (NDV); and the hemagglutinin neuraminidase (HN) protein of NDV. The present invention further relates to nucleic acids encoding for the recombinant oncolytic virus and vectors comprising the nucleic acids. The present invention further relates to pharmaceutical compositions comprising the rVSV of the invention, the nucleic acid or the vector, further to uses as gene delivery tool and/or for tumor detection. The present invention further relates to the recombinant oncolytic vesicular stomatitis virus (VSV) for use in medicine, in particular for the diagnosis, prevention and/or treatment of cancer.

Find Patent Forward Citations

Loading…